Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | ARG1 | P05089 | 1/20 | 0.44 |
| ▸ | ARG2 | P78540 | 1/20 | 0.44 |
| ▸ | NOS2 | P35228 | 3/20 | 0.40 |
| ▸ | NOS1 | P29475 | 2/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.34 |
| ▸ | BHMT | Q93088 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21335955 | 1.00 | ALDH1A1 (0.45) | ALDH1A1ALOX15ARG1ARG2NOS2 | |
| SCHEMBL19528477 | 0.79 | ARG1 (0.37) | ALDH1A1ALOX15ARG1ARG2NOS2 | |
| SCHEMBL16360438 | 0.77 | MEN1 (0.40) | ALDH1A1ALOX15ARG1ARG2NOS2 | |
| SCHEMBL1272927 | 0.77 | ARG1 (0.47) | ALDH1A1ALOX15ARG1ARG2NOS2 | |
| SCHEMBL13539874 | 0.77 | ALDH1A1 (0.36) | ALDH1A1ALOX15ARG1ARG2NOS2 | |
| SCHEMBL1272928 | 0.77 | ARG1 (0.47) | ALDH1A1ALOX15ARG1ARG2NOS2 | |
| SCHEMBL16830417 | 0.76 | ARG1 (0.43) | ALDH1A1ALOX15ARG1ARG2NOS2 | |
| SCHEMBL16830406 | 0.76 | ARG1 (0.43) | ALDH1A1ALOX15ARG1ARG2NOS2 | |
| SCHEMBL36934 | 0.75 | ARG1 (0.61) | ALDH1A1ALOX15ARG1ARG2NOS2 | |
| SCHEMBL36933 | 0.75 | ARG1 (0.61) | ALDH1A1ALOX15ARG1ARG2NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 246 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | AMBRX, INC. | 2024-07-16 | — | — | US | disclosed |
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | AMBRX, INC. | 2024-07-16 | — | — | US | disclosed |
| US-20230348547-A1 | MODIFIED BOVINE G-CSF POLYPEPTIDES AND THEIR USES | AMBRX INC (US) | 2023-11-02 | — | — | US | disclosed |
| US-11786578-B2 | Modified relaxin polypeptides and their uses | AMBRX, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11786578-B2 | Modified relaxin polypeptides and their uses | AMBRX, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230295320-A1 | Anti-CD70 Antibody Drug Conjugates | AMBRX, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295320-A1 | Anti-CD70 Antibody Drug Conjugates | AMBRX, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230226152-A1 | INTERLEUKIN-2 POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF | AMBRX, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20080113412-A1 | Blood plasma protein conjugated to apolipoproteins for use in treatment of metabolic disorders | AMBRX, INC. (US) | 2008-05-15 | — | — | US | disclosed |
| US-20080113412-A1 | Blood plasma protein conjugated to apolipoproteins for use in treatment of metabolic disorders | AMBRX, INC. (US) | 2008-05-15 | — | — | US | disclosed |
| US-20080107680-A1 | Modified Human Growth Hormone | AMBRX, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080107680-A1 | Modified Human Growth Hormone | AMBRX, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080102124-A1 | Modified Human Growth Hormone | AMBRX, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080102124-A1 | Modified Human Growth Hormone | AMBRX, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080102125-A1 | Modified Human Growth Hormone | AMBRX, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080102125-A1 | Modified Human Growth Hormone | AMBRX, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-7332571-B2 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332571-B2 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC. (US) | 2008-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226152-A1 | INTERLEUKIN-2 POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF | IL2, IL2RA, TAP2 | ALDH1A1 2074/4885ALOX15 1618/4885ARG1 2084/4885 |
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | CD74, CD63, CD47 | ALDH1A1 868/4885ALOX15 4277/4885ARG1 942/4885 |
| US-20080102124-A1 | Modified Human Growth Hormone | GHRHR, GHITM, GHSR | ALDH1A1 4658/4885ALOX15 4674/4885ARG1 1534/4885 |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | TLR3, TLR1, TLR9 | ALDH1A1 2172/4885ALOX15 868/4885ARG1 3033/4885 |
| US-20080102125-A1 | Modified Human Growth Hormone | GHRHR, GHITM, GHSR | ALDH1A1 4658/4885ALOX15 4674/4885ARG1 1534/4885 |
| US-20230348547-A1 | MODIFIED BOVINE G-CSF POLYPEPTIDES AND THEIR USES | CSF3R, GMFG, HDGF | ALDH1A1 4469/4885ALOX15 4686/4885ARG1 75/4885 |
| US-20080113412-A1 | Blood plasma protein conjugated to apolipoproteins for use in treatment of metabolic disorders | APOB, FABP1, HDLBP | ALDH1A1 2793/4885ALOX15 1923/4885ARG1 1261/4885 |
| US-20230295320-A1 | Anti-CD70 Antibody Drug Conjugates | CD63, CD74, CD99 | ALDH1A1 1177/4885ALOX15 3690/4885ARG1 1167/4885 |
| US-11786578-B2 | Modified relaxin polypeptides and their uses | RXFP1, RXFP2, RXFP3 | ALDH1A1 4777/4885ALOX15 3910/4885ARG1 39/4885 |
| US-20080107680-A1 | Modified Human Growth Hormone | GHRHR, GHITM, GHSR | ALDH1A1 4658/4885ALOX15 4674/4885ARG1 1534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.